



This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (amended): The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the general Formula I or II:



Formula I



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;


x is O, S, NH;

R is hydrogen, a linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> independently of one another represent hydrogen, a linear or branched (C<sub>1</sub> to C<sub>6</sub>) alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group, which may be unsubstituted or optionally substituted at the same or different carbon atoms with

one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups and pharmaceutically acceptable salts and prodrugs thereof; ~~for the manufacture of a drug product for the treatment of benign and malignant oncoeses wherein said alkylphosphocholine is administered~~ before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatin, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 2 (amended): ~~The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine using~~ compound having the structure of Formula I:



Formula I

where, independently of one another,

n is the integer 1 or 2;

m is the integer 1;


x is O;

R is H or a straight-chain or branched (C<sub>1</sub>-C<sub>17</sub>)-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> are, independently of one another, H or a straight-chain or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group;

~~for the manufacture of a drug product for the treatment of benign and malignant oncoeses wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.~~

Claim 3 (amended): ~~The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the general Formula II[[:] as claimed in claim 1~~



Formula II

where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched (C<sub>1</sub>-C<sub>17</sub>)-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> are, independently of one another, H or a straight-chain or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group;

~~for the manufacture of a drug product for the treatment of benign and malignant oncoeses wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.~~

Claim 4 (amended): ~~The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of using octadecyl 1,1-dimethylpiperidinium-4-yl phosphate as claimed in claim 1 for the manufacture of a drug product for the treatment of benign and malignant oncoeses wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.~~

Claim 5 (amended): ~~The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the general Formula I or II as claimed in any one of the preceding claims 1, 2, 3, or 4, in which the approved antitumor medicaments may be substance is chosen from alkylating agents, antimetabolites, plant alkaloids, platinum compounds, tumor antibiotics and agonists or antagonists of natural hormones.~~

Claim 6 (original): ~~The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound~~

of the general Formula I or II using alkylphosphocholines as claimed in ~~claim 5~~ claims 1, 2, 3, or 4, wherein the antitumor medicaments may be is chosen from cisplatin, cyclophosphamide or doxorubicin Adriamycin.

Claim 7 (amended): The A method of treating benign and malignant oncoses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the general Formula I or II as claimed in ~~any one of claims 1, 2, 3, and 4~~ claims 1, 2, 3, or 4, in which the approved antitumor medicaments may be is chosen from inhibitors of signal transduction in the form of high and low molecular weight inhibitors of receptor and/or cytosolic kinases.

Claim 8 (original): The A method of treating benign and malignant oncoses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II using an alkylphosphocholine as claimed in ~~claim 7~~ claims 1, 2, 3, or 4, where the inhibitors may be are chosen from monoclonal antibodies or heterocyclic compounds.

Claim 9 (amended): The A method of treating benign and malignant oncoses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the general Formula I or II as claimed in ~~any one of the preceding claims 1, 2, 3, or 4~~, in a therapeutic dose which is effective for the treatment before and/or during the treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabin.

Claim 10 (amended): The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the general Formula I or II as claimed in any one of the preceding claims 1, 2, 3, or 4, where the approved antitumor medicament substance is a combination of various cytostatics.

Claim 11 (amended): The A method of treating benign and malignant oncoeses, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound using alkylphosphocholines of the Formula I or II as claimed in any one of claims 1, 2, 3, and or 4 for the manufacture of a drug product for the treatment of benign and malignant oncoeses wherein said alkylphosphocholine is administered before and/or during the treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin, wherein the drug product comprises the customary pharmaceutical carriers, excipients and/or diluents in addition to the alkylphosphocholine of the Formula I or II.

Claim 12 (amended): A drug product comprising consisting essentially of an at least one alkylphosphocholine of the general Formula I or II as in claim 4 claims 1, 2, 3, or 4 and, where appropriate, carriers and/or excipients for use in the treatment of benign and malignant oncoeses wherein the drug product is administered before and/or during the treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.